About NovelStem
NovelStem is a publicly listed company based in Boca Raton (United States) founded in 1993 by Mitchell Rubenstein. Stem cell diagnostics for predicting cancer chemotherapy resistance are developed. Its chief executive, as recorded, is Mitchell Rubenstein. NovelStem offers products and services including Diagnostic Technology and Net Force Publishing Franchise. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Diversified. Its legal entity is NOVELSTEM INTERNATIONAL CORP. Its competitors include Isabl, CytoSite Bio and AccuTheranostics; 2 of its 3 listed competitors have raised funding.
Company details
NovelStem was founded in 1993 and is headquartered in Boca Raton, United States. Operations focus on biotechnology, where proprietary haploid human embryonic stem cell technology, known as NewStem, is utilized to create diagnostics that predict patient resistance to cancer chemotherapies. Additional efforts include development of therapeutics and applications in reproductive medicine.
- Headquarters Boca Raton, United States
- Founders Mitchell Rubenstein
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website novelstem.com
- Social LinkedIn
- Legal Name Novelstem International Corp.
- Net Profit$2.38 M (USD)as on Dec 31, 2025
- EBITDA-$238.76 K (USD)72.9as on Dec 31, 2025
- Investors
Products & Services of NovelStem
NovelStem offers a comprehensive portfolio of products and services, including Diagnostic Technology and Net Force Publishing Franchise.
Predicts drug resistance for targeted cancer therapies using stem cells.
Manages book series relaunch and licensing agreements.
Funding Insights of NovelStem
- Total Rounds 2
- First Round $700,000
(Dec 2010)
- Investors Count 1
All 2 funding rounds of NovelStem with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2016 | Private Equity Round | – | PJ SOLOMON | – | |
| Dec 2010 | $700,000 | Unspecified | – | – | – |
1 investors in total: 1 institutional.
Investors in NovelStem
NovelStem has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include PJ SOLOMON.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
M&A advisory and restructuring services are provided across sectors. | 1989 | pjsolomon.com | New York, United States |
Investor details for NovelStem
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of NovelStem
1 people are tracked at NovelStem (1 in leadership).
| Name | Role | Group |
|---|---|---|
Mitchell Rubenstein | Founder & CEO | Leadership |
Complete people profiles for NovelStem
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of NovelStem
NovelStem is a publicly listed company on the OTC with ticker symbol NSTM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date12 Nov 1993
- Listed onOTC: NSTM
- Listed entityNovelStem International Corp.
- Exchange sectorHealth technology
- ISINUS67001V1098
- Share price$0.01 · 2026-10-07
- Market capitalisation$468,658.00
- Price to earnings1.3
- EPS (diluted, trailing year)$-0.01
- Volume (last session)11,938
Financials of NovelStem
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $2.4M | -$238,760 | |
| 2024 | -$3.2M | -$880,950 | |
| 2023 | -$4.2M | -$665,280 | |
| 2022 | -$1.1M | -$744,430 | |
| 2013 | $424,750 | $6.2M | -$4.8M |
Detailed financial statements for NovelStem
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of NovelStem
4 dated milestones of NovelStem across 23 years, from founding to its latest funding, stage changes and deals.
- Founded NovelStem is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $700K.
- Funding Latest funding round, Private Equity Round,.
Competitors of NovelStem
NovelStem has 3 listed competitors in our database, 2 of them funded. They include Isabl, CytoSite Bio and AccuTheranostics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| isabl.io | 2020 | New York, United States | $3M | 3 | Cancer patients' genomes are analyzed by a medical diagnosis platform. | |
| cytositebio.com | 2016 | United States | $7.49M | Precision imaging products for immuno-oncology therapy are developed. | ||
| accutheranostics.com | 2012 | Buffalo, United States | Personalized chemotherapy response testing is offered for cancer patients. |
Detailed competitors of NovelStem
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as NovelStem (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Novelstem
Complete news archive for NovelStem
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NovelStem
NovelStem was founded in 1993 and raised its 1st funding round 17 years after it was founded.
NovelStem is headquartered in Boca Raton, United States. It is registered at Boca Raton, Florida, United States.
Mitchell Rubenstein is the CEO of NovelStem, as recorded in our data. They have also founded this company.
NovelStem was founded in 1993 and is headquartered in Boca Raton, United States. Operations focus on biotechnology, where proprietary haploid human embryonic stem cell technology, known as NewStem, is utilized to create diagnostics that predict patient resistance to cancer chemotherapies. Additional efforts include development of therapeutics and applications in reproductive medicine.
NovelStem's top competitors include CytoSite Bio, Isabl and AccuTheranostics.
NovelStem offers Diagnostic Technology and Net Force Publishing Franchise.
Yes, NovelStem is publicly traded on OTC under the ticker symbol NSTM.
NovelStem has 1 investor. Key investors include PJ SOLOMON.
NovelStem operates through Novelstem International Corp..